Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
100.13B
Market cap100.13B
Price-Earnings ratio
16.61
Price-Earnings ratio16.61
Dividend yield
5.04%
Dividend yield5.04%
Average volume
14.83M
Average volume14.83M
High today
$49.37
High today$49.37
Low today
$49.01
Low today$49.01
Open price
$49.21
Open price$49.21
Volume
6.19M
Volume6.19M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $49.20. The company's market cap stands at 100.13B, with a P/E ratio of 16.61 and a dividend yield of 5.0%.

As of 2025-11-30, Bristol-Myers Squibb(BMY) stock has fluctuated between $49.01 and $49.37. The current price stands at $49.20, placing the stock +0.4% above today's low and -0.3% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 6.19M, compared to an average daily volume of 14.83M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

BMY News

Nasdaq 2d
Validea Detailed Fundamental Analysis - BMY

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Low PE Investor m...

Validea Detailed Fundamental Analysis - BMY
The Motley Fool 3d
Bristol-Myers Earnings Call Transcript

Image source: The Motley Fool. Oct. 30, 2025 at 4:06 p.m. ET Call participants Board Chair and Chief Executive Officer — Christopher Boerner Chief Financial Of...

Bristol-Myers Earnings Call Transcript
Benzinga 6d
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BM...

Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Analyst ratings

70%

of 30 ratings
Buy
26.7%
Hold
70%
Sell
3.3%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.